The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James https://cancer.osu.edu) is dedicated to creating a cancer-free world by integrating scientific research with excellence in education and patient-centered care – a strategy that leads to better methods of prevention, detection and treatment.
Ohio State has been designated a National Cancer Institute (NCI) Comprehensive Cancer Center for nearly 50 years and is one of only a few centers funded by the NCI to conduct phase I, II and III clinical trials on novel anticancer drugs provided by the NCI. In its last three formal reviews for five-year redesignation, the university’s cancer program, embodied in the OSUCCC – James, has received the NCI’s highest descriptor of “exceptional.”
The OSUCCC – James has $140 million in active cancer-relevant research funding, and over $76 million of that total – more than half – comes from the NCI. In 2023 alone, Ohio State cancer researchers received 46 new research grants from the NCI.
Cancer research
The OSUCCC – James has over 320 full or introductory cancer researchers who collectively represent 12 of the 15 colleges at Ohio State. Each researcher is a member of one of five multidisciplinary research programs: Cancer Control; Leukemia and Hematologic Malignancies; Cancer Biology; Molecular Carcinogenesis and Chemoprevention; or Translational Therapeutics. In 2023, these researchers authored or co-authored 941 publications in peer-reviewed journals. In addition, OSUCCC – James researchers opened 140 clinical trials in 2023, bringing the total number of cancer clinical trials at Ohio State to approximately 650. These studies offer the latest cancer treatments, some of which are available nowhere else.
As the cancer program’s 356-bed adult patient-care component, The James is the third-largest cancer hospital in the United States and one of the top cancer hospitals in the nation as ranked by U.S. News & World Report. With 21 floors and more than 1.1 million square feet, The James is a transformational facility that fosters collaboration and integration of cancer research and clinical care. Because early diagnosis is the key to successful cancer treatment, The James Cancer Diagnostic Center at the OSUCCC – James provides patients who may have cancer with direct, expedited access to diagnostic testing.
The OSUCCC – James since 2014 has enrolled nearly 70,000 patients in a Total Cancer Care® (TCC) protocol for voluntarily sharing de-identified clinical data that advances cancer research and personalizes cancer care. The TCC protocol has been adopted by all 19 member institutions across the United States that constitute the Oncology Research Information Exchange Network (ORIEN), a research collaboration co-founded and co-anchored by the OSUCCC – James and Moffit Cancer Center in Tampa, Florida. Through ORIEN, TCC-consented patients across the United States donate clinical data for research that helps scientists better understand cancer at the molecular level.
International reputation and global destination
Because of its international reputation for providing outstanding research-based cancer care, the OSUCCC – James is regarded as a global destination of choice, serving patients from all 50 U.S. states, three U.S territories and 90 other countries. The institution’s Destination Medicine Global Health Care team is dedicated to ensuring that distance and language are no obstacles to receiving the internationally recognized cancer care available at Ohio State.
